Merck ends development of BTK inhibitor nemtabrutinib | Seeking Alpha



























Merck Research Facility South San Francisco

JasonDoiy

  • Merck (MRK) has abandoned development of the oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor nemtabrutinib after a Data Monitoring Committee evaluating a phase 3 trial suggested the benefits of the therapy may not outweigh the risks.
  • The pharma made its

Source link

Leave a Reply

Discover more from Occasional Digest

Subscribe now to keep reading and get access to the full archive.

Continue reading